Document Type

Poster Presentation

Publication Date

Spring 4-19-2024

Date Assignment Submitted



Major Depressive Disorder (MDD), also known as clinical depression, is a serious problem in our society as an estimated 21 million American suffer for this clinical condition. A main strategy for the treatment of MDD involves the inhabitation of the reuptake of serotonin and/or noradrenaline. To correct this problem selective serotonin reuptake inhibitors (SSRIs) and monoamine oxidase inhibitors (MAOIs) are commonly used for the treatment of MDD.

This traditional treatment approach has many side effects, which include gastrointestinal problems, insomnia, cognitive impairment, and activation and aggravation of psychosis, etc. Additionally, about 20% of patients do not respond to such treatments, and many who do respond, eventually relapse. To overcome the deficiencies of the present-day antidepressants there is an urgent need to discover the alternative antidepressants with lesser or no side effects. In this pursuit, psilocybin which is found in “magic mushrooms” has been recently shown to relieve MDD symptoms rapidly and with sustained benefit over the period of several months.

In this mini review, we will summarize the recent research on psilocybin as a potential antidepressant. We believe, our summary will facilitate further research in the thorough assessment of the risks and benefits of the use of psilocybin as a drug for the treatment of clinical depression.


Lynn University


Lynn University Student Research Symposium


Poster Presentation: Natural Science category


Boca Raton, FL


College of Arts and Sciences



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.